2012
DOI: 10.1016/j.ijrobp.2010.10.041
|View full text |Cite
|
Sign up to set email alerts
|

Intensity-Modulated Radiotherapy in the Treatment of Oropharyngeal Cancer: An Update of the Memorial Sloan-Kettering Cancer Center Experience

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

9
114
1
3

Year Published

2013
2013
2018
2018

Publication Types

Select...
8
2

Relationship

1
9

Authors

Journals

citations
Cited by 170 publications
(127 citation statements)
references
References 37 publications
9
114
1
3
Order By: Relevance
“…Pretreatment evaluation and imaging protocols for each institution have previously been described. [10][11][12] Treatment decisions were made by a multidisciplinary head and neck cancer team according to institutional practice guidelines. Radiotherapy fractionation schedules were divided into four categories: conventional, moderately accelerated, accelerated and hyperfractionated.…”
Section: Methodsmentioning
confidence: 99%
“…Pretreatment evaluation and imaging protocols for each institution have previously been described. [10][11][12] Treatment decisions were made by a multidisciplinary head and neck cancer team according to institutional practice guidelines. Radiotherapy fractionation schedules were divided into four categories: conventional, moderately accelerated, accelerated and hyperfractionated.…”
Section: Methodsmentioning
confidence: 99%
“…The characteristics of the patients are listed in Table 1. All patients were treated with intensitymodulated radiation therapy with dose prescriptions of 70 Gy for gross disease, 59.4 Gy for high-risk regions, and 50 to 54 Gy for low-risk regions [19,20] . …”
Section: Patientsmentioning
confidence: 99%
“…Rates of clinically significant late xerostomia up to 40% are seen, despite constraining the dose delivered to the contralateral parotid gland. [15,16,[37][38][39] For some patients with bilateral cervical nodal metastases or bulky primary disease crossing midline, it is not possible to deliver parotid sparing RT for fear of compromising dose to tumour and subsequent disease control. Most of these patients will develop RIX as a late, permanent and significant toxicity.…”
Section: Discussionmentioning
confidence: 99%